US5227508A
Expired / Lapsed
US
⏱️ 0.0 years remaining
3-deoxy-3-substituted analogs of phosphatidylinositol
Assignee: Mayo Clinic in Florida
•
Filing: 1992-01-24
•
Granted: 1993-07-13
•
Expires: 2012-01-24
Abstract
Abstract The invention provides 3-deoxy-3-substituted analogs of phosphatidylinositol which are useful to inhibit the growth of mammalian cells, i.e., to treat neoplastic conditions and other proliferative disorders of mammalian cells.
Inventors
- 👤 Alan P. Kozikowski
- 👤 Werner Tuckmantel
- 👤 Abdul H. Faug
- 👤 Garth Powis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 17:13
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/06; C07F9/22; C07F9/24; C07F9/2404; C07F9/2416; C07F9/08; C07F9/09; C07F9/117; C07F9/28; C07F9/38; C07F9/40; C07F9/4003; C07F9/4018
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
153 words
A 3-deoxy-3-substituted analog of phosphatidyl inositol of formula: ##STR5## or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of halo, N 3 , CN, --NC, OR, SR, N(R) 2 , CO 2 R, C(O)R, P(O)(OR) 2 , CF 3 , S(O)R and SO 2 R; wherein each R is H, (C 1 -C 22 )alkyl, (C 6 -C 10 )aryl, (C 3 -C 8 )-cycloalkyl, (C 2 -C 22 )alkenyl, (C 5 -C 8 )cycloalkenyl, (C 7 -C 32 )-aralkyl, (C 7 -C 32 )alkylaryl, (C 9 -C 32 )aralkenyl or (C 9 -C 32 )-alkenylaryl; n is 0 or 1, with the proviso that when n is O, X is not OH, Y is O, S, NR, CH 2 , CF 2 or CHF; and Z is ##STR6## wherein R 1 and R 2 are individually R, --C(O)R, --CO 2 R, --C(O)NHR, C(O)SR or P(O)(OR) 2 .
Claim 2
Dependent Claim
153 words
A 3-deoxy-3-substituted analog of phosphatidyl inositol of formula: ##STR5## or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of halo, N 3 , CN, --NC, OR, SR, N(R) 2 , CO 2 R, C(O)R, P(O)(OR) 2 , CF 3 , S(O)R and SO 2 R; wherein each R is H, (C 1 -C 22 )alkyl, (C 6 -C 10 )aryl, (C 3 -C 8 )-cycloalkyl, (C 2 -C 22 )alkenyl, (C 5 -C 8 )cycloalkenyl, (C 7 -C 32 )-aralkyl, (C 7 -C 32 )alkylaryl, (C 9 -C 32 )aralkenyl or (C 9 -C 32 )-alkenylaryl; n is 0 or 1, with the proviso that when n is O, X is not OH, Y is O, S, NR, CH 2 , CF 2 or CHF; and Z is ##STR6## wherein R 1 and R 2 are individually R, --C(O)R, --CO 2 R, --C(O)NHR, C(O)SR or P(O)(OR) 2 .
Claim 3
Dependent Claim
15 words
The compound of claim 1 wherein Y is O, CH 2 or CF 2 .
Claim 4
Dependent Claim
11 words
The compound of claims 1 or 2 wherein n is 0.
Claim 5
Dependent Claim
32 words
The compound of claims 1 or 2 wherein R 1 and R 2 are individually (C 1 -C- 22 )alkyl, (C 12 -C 22 ) alkanoyl or (C 12 -C 22 )alkenoyl.
Claim 6
Dependent Claim
9 words
The compound of claim 3 wherein X is halo.
Claim 7
Dependent Claim
9 words
The compound of claim 5 wherein X is F.
Claim 8
Dependent Claim
8 words
The compound of claim 3 wherein X amino.
Claim 9
Dependent Claim
11 words
The compound of claim 3 wherein X is N 3 .
Claim 10
Dependent Claim
14 words
The compound of claim 4 wherein X is P(O)(OR) 2 and n is 1.
Claim 11
Dependent Claim
9 words
The compound of claim 9 wherein R is H.
Claim 12
Dependent Claim
3 words
3-amino-3-deoxy-D-myo-inositol[(R)-2,3-bis(hexadecanoyloxy)propyl] hydrogen phosphate.
Claim 13
Dependent Claim
3 words
3-amino-3-deoxy-D-myo-inositol[(R)-2,3-bis(hexadecanoyloxy)propyl] hydrogen phosphate.
Claim 14
Dependent Claim
3 words
3-deoxy-3-fluoro-D-myo-inositol[(R)-2,3-bis(hexadecanoyloxy)propyl] hydrogen phosphate.
Claim 15
Dependent Claim
3 words
3-deoxy-3-fluoro-D-myo-inositol[(R)-2,3-bis(hexadecanoyloxy)propyl] hydrogen phosphate.
Claim 16
Dependent Claim
3 words
3-deoxy-3-phosphonomethyl-D-myo-inositol[(R)-2,3-bis(hexadecanoyloxy)propyl] hydrogen phosphate.
Claim 17
Dependent Claim
3 words
3-deoxy-3-phosphonomethyl-D-myo-inositol[(R)-2,3-bis(hexadecanoyloxy)propyl] hydrogen phosphate.
Claim 18
Dependent Claim
1 words
1-(O-[(R)-2,3-bis(hexadecanoyloxy)propyl]phosphonomethyl)-1,3-dideoxy-3-fluoro-D-myo-inositol.
Claim 19
Dependent Claim
1 words
1-(O-[(R)-2,3-bis(hexadecanoyloxy)propyl]phosphonomethyl)-1,3-dideoxy-3-fluoro-D-myo-inositol.
Claim 20
Dependent Claim
1 words
1-[[O-[(R)-2,3-bis(hexadecanoyloxy)propyl]phosphonyl]difluoromethyl]-1,3-dideoxy-3-fluoro-D-myo-inositol.
Claim 21
Dependent Claim
1 words
1-[[O-[(R)-2,3-bis(hexadecanoyloxy)propyl]phosphonyl]difluoromethyl]-1,3-dideoxy-3-fluoro-D-myo-inositol.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-07-12 | 1997-01-11 | 1997-07-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-07-12 | 2001-01-11 | 2001-07-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-07-12 | 2005-01-11 | 2005-07-13 | $7700.00 | Window Closed / Lapsed |